Skip to main content
. 2023 Nov 22;6(4):805–827. doi: 10.20517/cdr.2023.77

Figure 3.

Figure 3

(A) Schematic illustration of the construction of sequentially responsive nanosystem (DOX@RPMSNs) and dual-responsive drug release; (B) Total ATP concentrations of MCF7/ADR cells treated with H2O2 and different doses of RPMSNs; (C) The expression levels of P-gp in tumor cells with different treatments; (D) Changes of tumor volume in tumor-bearing mice with different treatments (*P < 0.05, **P < 0.01, ***P < 0.001). This figure is quoted with permission from Liu et al.[62]; (E) Schematic illustration of the construction of co-delivery nanosystem (HPMSNs) and dual-responsive drug release; (F) The expression levels of P-gp and GCN5 in tumor cells with different treatments; (G) Changes of tumor weight in tumor-bearing mice with different treatments (*P < 0.05, **P < 0.01). This figure is quoted with permission from Yuan et al.[68]. DOX: Doxorubicin; PEG-b-PLLDA: poly (ethylene glycol) amine derivative shell.